Economic Evaluation of Childhood 7-Valent Pneumococcal Conjugate Vaccination in Korea

Sohn, Hyun Soon; Suh, Dong‐Churl; Jang, Eun-Jin; Kwon, Jin-Won

doi:10.18553/jmcp.2010.16.1.32

Cited by 18 publications

(36 citation statements)

References 46 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All studies were based on (cohort-based) decision analysis models; some used a decision tree [21,[25][26][27][30][31][32] and others the slightly more complex Markov models. [7,15,16,18,20,[22][23][24]28,29,33,34] Table II lists the selected studies and their general Excluded records (n = 5)…”

Section: Search Resultsmentioning

confidence: 99%

“…Twelve studies were performed in eight European countries, [15][16][17][18]20,21,[25][26][27]29,30,34] five in North America, [7,23,24,28,33] two in South America [22,32] and one each in Australia [19] and Asia. [31] All but one study reported on the cost effectiveness of PCV7. This one study concerned a combined 9-valent pneumococcal and meningococcal B vaccine.…”

Section: Search Resultsmentioning

confidence: 99%

“…PCV7, the combined pneumococcal NTHi vaccine and a hypothetical combined pneumococcus-NTHi-Moraxella catarrhalis vaccine). [7] Five studies focused primarily on pneumococcal otitis media; [17,18,23,31,34] the other studies on all-cause otitis media. The vaccine schedule consisted of four doses administered before the age of 18 months, except for the Swedish and Brazilian studies, which used three doses.…”

Section: Search Resultsmentioning

confidence: 99%

“…[16,30,32] Eighteen studies used a societal perspective, whereas three studies used the healthcare payer's perspective. [26,28,31] Four studies included herd immunity in their model. [25,26,28,34] Thirteen of the 21 studies had pharmaceutical company involvement (either by means of co-authors, grants or direct involvement by the pharmaceutical company).…”

Section: Search Resultsmentioning

confidence: 99%

“…[4,9] In these trials, the vaccine efficacy against all-cause AOM varied between 5.8% and 8.3% (table II). Nevertheless, three economic evaluations [20,28,31] assumed considerably different vaccine efficacy for PCV7 than that reported in the US and Finnish studies. By including herd effects, Ray et al [28] assumed a vaccine efficacy of 12.9%.…”

Section: Vaccine Efficacymentioning

confidence: 98%

See 4 more Smart Citations

Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children

et al. 2011

View full text Add to dashboard Cite

While pneumococcal conjugate vaccines have shown to be highly effective against invasive pneumococcal disease, their potential effectiveness against acute otitis media (AOM) might become a major economic driver for implementing these vaccines in national immunization programmes. However, the relationship between the costs and benefits of available vaccines remains a controversial topic. Our objective is to systematically review the literature on the cost effectiveness of pneumococcal conjugate vaccination against AOM in children. We searched PubMed, Cochrane and the Centre for Reviews and Dissemination databases (Database of Abstracts of Reviews of Effects [DARE], NHS Economic Evaluation Database [NHS EED] and Health Technology Assessment database [HTA]) from inception until 18 February 2010. We used the following keywords with their synonyms: 'otitis media', 'children', 'cost-effectiveness', 'costs' and 'vaccine'. Costs per AOM episode averted were calculated based on the information in this literature. A total of 21 studies evaluating the cost effectiveness of pneumococcal conjugate vaccines were included. The quality of the included studies was moderate to good. The cost per AOM episode averted varied from &U20AC;168 to &U20AC;4214, and assumed incidence rates varied from 20,952 to 118,000 per 100,000 children aged 0-10 years. Assumptions regarding direct and indirect costs varied between studies. The assumed vaccine efficacy of the 7-valent pneumococcal CRM197-conjugate vaccine was mainly adopted from two trials, which reported 6-8% efficacy. However, some studies assumed additional effects such as herd immunity or only took into account AOM episodes caused by serotypes included in the vaccine, which resulted in efficacy rates varying from 12% to 57%. Costs per AOM episode averted were inversely related to the assumed incidence rates of AOM and to the estimated costs per AOM episode. The median costs per AOM episode averted tended to be lower in industry-sponsored studies. Key assumptions regarding the incidence and costs of AOM episodes have major implications for the estimated cost effectiveness of pneumococcal conjugate vaccination against AOM. Uniform methods for estimating direct and indirect costs of AOM should be agreed upon to reliably compare the cost effectiveness of available and future pneumococcal vaccines against AOM.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Section: Search Resultsmentioning

confidence: 99%

Section: Search Resultsmentioning

confidence: 99%

Section: Search Resultsmentioning

confidence: 99%

Section: Vaccine Efficacymentioning

confidence: 98%

See 3 more Smart Citations

Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children

et al. 2011

View full text Add to dashboard Cite

show abstract

Cost-Effectiveness Analysis of Pneumococcal Conjugate Vaccine in Taiwan: A Transmission Dynamic Modeling Approach

Wu¹,

Chang

Huang

et al. 2012

Value in Health

View full text Add to dashboard Cite

show abstract

Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions

et al. 2019

View full text Add to dashboard Cite

Background: Pneumococcal diseases cause substantial mortality, morbidity, and economic burden. Evidence on data inputs for economic evaluations of interventions targeting pneumococcal disease is critical.Objectives: To summarize evidence on resource use, costs, health utilities, and cost-effectiveness for pneumococcal disease and associated interventions to inform future economic analyses.Methods: We searched MEDLINE, Embase, Web of Science, CINAHL, PsycINFO, EconLit, and Cochrane databases for peerreviewed studies in English on pneumococcal disease that reported health utilities using direct or indirect valuation methods, resource use, costs, or cost-effectiveness of intervention programs, and summarized the evidence descriptively. Results:We included 383 studies: 9 reporting health utilities, 131 resource use, 160 economic costs of pneumococcal disease, 95 both resource use and costs, and 178 economic evaluations of pneumococcal intervention programs. Health state utility values ranged from 0 to 1 for both meningitis and otitis media and from 0.3 to 0.7 for both pneumonia and sepsis. Hospitalization was shortest for otitis media (range: 0.1-5 days) and longest for sepsis/septicemia (6-48). The main categories of costs reported were drugs, hospitalization, and household or employer costs. Resource use was reported in hospital length of stay and number of contacts with general practitioners. Costs and resource use significantly varied among population ages, disease conditions, and settings. Current vaccination programs for both adults and children, antibiotic use and outreach programs to promote vaccination, early disease detection, and educational programs are cost-effective in most countries. Conclusion:This study has generated a comprehensive repository of health economic evidence on pneumococcal disease that can be used to inform future economic evaluations of pneumococcal disease intervention programs.

show abstract

Economic Evaluation of Childhood 7-Valent Pneumococcal Conjugate Vaccination in Korea

Cited by 18 publications

References 46 publications

Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children

Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children

Cost-Effectiveness Analysis of Pneumococcal Conjugate Vaccine in Taiwan: A Transmission Dynamic Modeling Approach

Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions

Contact Info

Product

Resources

About